85 results
8-K
TXMD
TherapeuticsMD Inc
10 Jul 23
Changes in Registrant's Certifying Accountant
5:20pm
years ended December 31, 2022 and December 31, 2021 and the subsequent period to the date of its engagement, neither the Company nor anyone acting
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
Days after its engagement). The Firm shall make its determination only with respect to the matters still in dispute and, with respect to each
8-K
pc5ki5o5k48bk2h4d
25 Jul 22
Entry into a Material Definitive Agreement
8:00am
SC 14D9/A
1eligc7wmko58jrh78
28 Jun 22
Tender offer solicitation (amended)
4:31pm
SC 14D9
pwq8s
10 Jun 22
Tender offer solicitation
6:51pm
SC TO-T
EX-99
t0scqywcvcq2u72mq
6 Jun 22
Third party tender offer statement
5:02pm
8-K
EX-2.1
avuf7e 2hdlenfxz2
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
8-K
EX-99.2
x2l3ro2
4 Aug 21
TherapeuticsMD Announces Second Quarter 2021 Financial Results
7:00am
8-K
EX-99.1
3g6yrs k8
4 Aug 21
TherapeuticsMD Announces Second Quarter 2021 Financial Results
7:00am
8-K
EX-1.1
dfxl7834pxw9p3v696ge
16 Feb 21
Entry into a Material Definitive Agreement
8:35am
8-K
EX-99.1
tjqvk5stf6 l9931q
13 Jan 21
Entry into a Material Definitive Agreement
8:50am
8-K
EX-1.1
m7wn152
13 Nov 20
Entry into a Material Definitive Agreement
12:00am